Dr. Kim Discusses PD-L1 as a Biomarker in Lung Cancer

Edward S. Kim, MD
Published: Wednesday, Dec 20, 2017



Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses PD-L1 as a biomarker in lung cancer.

Although PD-L1 has been contested as a reliable biomarker in lung cancer, Kim says that it is useful for selecting patients to receive frontline immunotherapy.
 
SELECTED
LANGUAGE


Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses PD-L1 as a biomarker in lung cancer.

Although PD-L1 has been contested as a reliable biomarker in lung cancer, Kim says that it is useful for selecting patients to receive frontline immunotherapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x